α3 integrin-binding peptide-functionalized polymersomes loaded with volasertib for dually-targeted molecular therapy for ovarian cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
α3 integrin-binding peptide-functionalized polymersomes loaded with volasertib for dually-targeted molecular therapy for ovarian cancer
Authors
Keywords
PLK1 inhibitor, Targeted delivery, Polymersomes, Targeted therapy, Ovarian cancer
Journal
Acta Biomaterialia
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-02-07
DOI
10.1016/j.actbio.2021.02.007
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel monoclonal antibody against integrin α3 shows therapeutic potential for ovarian cancer
- (2020) Feng‐Yi Ke et al. CANCER SCIENCE
- GE11 peptide-installed chimaeric polymersomes tailor-made for high-efficiency EGFR-targeted protein therapy of orthotopic hepatocellular carcinoma
- (2020) Cheng Zhou et al. Acta Biomaterialia
- Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation
- (2020) Wenxing Gu et al. JOURNAL OF CONTROLLED RELEASE
- Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy
- (2020) Yuan Li et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer
- (2019) Xiaofei Xin et al. ACS Applied Materials & Interfaces
- Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability
- (2019) Monika Raab et al. NEOPLASIA
- Ligand density on nanoparticles: A parameter with critical impact on nanomedicine
- (2019) Alaaldin M. Alkilany et al. ADVANCED DRUG DELIVERY REVIEWS
- CD44‐Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma
- (2019) Wenxing Gu et al. ADVANCED MATERIALS
- The emergence of drug resistance to targeted therapies: Clinical evidence
- (2019) Ana Bela Sarmento-Ribeiro et al. DRUG RESISTANCE UPDATES
- Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors
- (2019) Chenglong Wang et al. Acta Biomaterialia
- Sensitization to oxidative stress and G2/M cell cycle arrest by histone deacetylase inhibition in hepatocellular carcinoma cells
- (2019) Hae-Ahm Lee et al. FREE RADICAL BIOLOGY AND MEDICINE
- Ovarian cancer statistics, 2018
- (2018) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma
- (2018) Ka-Kui Chan et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting the tumour stroma to improve cancer therapy
- (2018) Kenneth C. Valkenburg et al. Nature Reviews Clinical Oncology
- Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of polo-like kinase 1 and microtubule dynamics
- (2018) Sabrina Noack et al. Oncotarget
- Therapeutic enhancement of a cytotoxic agent using Photochemical internalisation in 3D compressed collagen constructs of ovarian cancer
- (2018) Layla Mohammad Hadi et al. Acta Biomaterialia
- Epigenetics in ovarian cancer: premise, properties, and perspectives
- (2018) Qilian Yang et al. Molecular Cancer
- HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression
- (2018) Jasmina Makarević et al. Cells
- Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain-targeting chimaeric polymersomes
- (2018) Yanan Shi et al. JOURNAL OF CONTROLLED RELEASE
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- PLK1, A Potential Target for Cancer Therapy
- (2017) Zhixian Liu et al. Translational Oncology
- Co-delivery of Se nanoparticles and pooled SiRNAs for overcoming drug resistance mediated by P-glycoprotein and class III β-tubulin in drug-resistant breast cancers
- (2016) Wenjing Zheng et al. Acta Biomaterialia
- Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer
- (2016) Fang Ren et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
- (2016) Wen Li et al. DRUG RESISTANCE UPDATES
- Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study
- (2016) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Precision targeted therapy of ovarian cancer
- (2016) Justin Sapiezynski et al. JOURNAL OF CONTROLLED RELEASE
- Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor
- (2016) J. Van den Bossche et al. MEDICINAL RESEARCH REVIEWS
- Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
- (2016) Rosie Elizabeth Ann Gutteridge et al. MOLECULAR CANCER THERAPEUTICS
- Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
- (2016) Angela George et al. Nature Reviews Clinical Oncology
- Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
- (2016) Michael Ramirez et al. Nature Communications
- Ovarian cancer
- (2016) Ursula A. Matulonis et al. Nature Reviews Disease Primers
- Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels
- (2015) Jörg Haupenthal et al. NEOPLASIA
- Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer
- (2014) Wenbing Dai et al. BIOMATERIALS
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
- (2014) B T Gjertsen et al. LEUKEMIA
- Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects
- (2013) Wantong Song et al. Acta Biomaterialia
- "OA02" Peptide Facilitates the Precise Targeting of Paclitaxel-Loaded Micellar Nanoparticles to Ovarian Cancer In Vivo
- (2012) K. Xiao et al. CANCER RESEARCH
- Effect of ligand density, receptor density, and nanoparticle size on cell targeting
- (2012) Drew R. Elias et al. Nanomedicine-Nanotechnology Biology and Medicine
- A combinatorial extracellular matrix platform identifies cell-extracellular matrix interactions that correlate with metastasis
- (2012) Nathan E. Reticker-Flynn et al. Nature Communications
- Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics
- (2011) Timothy A. Yap et al. Annual Review of Pharmacology and Toxicology
- Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
- (2011) Twan Lammers et al. JOURNAL OF CONTROLLED RELEASE
- WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin 3
- (2009) C. Gourley et al. CANCER RESEARCH
- BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
- (2009) D. Rudolph et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search